Zofran Tablets The FDA has approved a new formulation of Glaxo Wellcome’s Zofran (ondansetron HCL), an oral 5HT3 antagonist antiemetic for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy in adults and children (ages four and older), for the prevention of nausea and vomiting associated with radiotherapy in adults, and for the prevention of post-operative nausea and vomiting in adults. The new formulation, known as Zofran ODT (ondansetron) Orally Disintegrating Tablets, incorporates a novel, freeze-dried technology. The Strawberry flavored tablet disintegrates instantly when placed on patient’s tongue and does not require water to aid in swallowing. Available since 1991, Zofran is the most used 5HT3 antagonist for the prevention of cancer chemotherapy-induced nausea and vomiting. Based on data collected since 1994, Zofran has been used in over 60 million chemotherapy treatments in the United States. The most commonly reported adverse effects are headache, diarrhea, constipation, fever, and malaise/fatigue.
			Copyright © 2008 Bay Area Breast Cancer Network. All rights reserved. [Home] [We're Here] [Breast Health] [News & Views] [Voices] [Make a Difference]